Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP issued a shareholder alert for Capricor Therapeutics (NASDAQ: CAPR) investors, publicizing the September 28, 2026 lead plaintiff deadline in a pending securities class action covering purchases between December 17, 2025 and July 26, 2026. The release recaps the FDA's extension of the PDUFA target action date for deramiocel, Capricor's lead cell therapy for Duchenne muscular dystrophy, from August 22 to November 22, 2026, after the agency classified the company's post-AdCom submission (24-month HOPE-3 open-label data and a refined upper-limb-function indication) as a major amendment.
Key figures
- Adcom vote
- 9-3 against efficacy
- Class period
- Dec. 17, 2025 - July 26, 2026
- Post crash close
- 7
- Dec2025 close gain
- $23.60
- Dec2025 price surge
- 370%
- Jul2026 price crash
- 64%
- Pdufa target date new
- November 22, 2026
- Dec2025 offering price
- $25 per share
- Dec2025 offering shares
- approximately 6 million
- Lead plaintiff deadline
- September 28, 2026
- Pdufa target date prior
- August 22, 2026
- Open label data duration
- 24-month
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.